These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Action of endogenous steroid inhibitors of brain aromatase relative to fadrozole.
    Author: Wozniak A, Hutchison JB.
    Journal: J Steroid Biochem Mol Biol; 1993 Mar; 44(4-6):641-5. PubMed ID: 8476776.
    Abstract:
    To study mechanisms of aromatase inhibition in brain cells, a highly effective non-steroidal aromatase inhibitor (Fadrozole; 4-[5,6,7,8-tetra-hydroimidazo- (1,5-a)-pyridin-5-yl] benzonitrile HCl; CGS 16949A) was compared with endogenous C-19 steroids, known to be formed in the preoptic area, which inhibit oestrogen formation. Using a sensitive in vitro tritiated water assay for aromatase activity in avian (dove) preoptic tissue, the order of potency, with testosterone as substrate was: Fadrozole (Ki < 1 x 10(-9) M) > 4-androstenedione > 5 alpha-androstanedione > 5 alpha-dihydrotestosterone (Ki = 6 x 10(-8) M) > 5 beta-androstanedione > 5 beta-dihydrotestosterone (Ki = 3.5 x 10(-7) M) > 5 alpha-androstane-3 alpha,17 beta-diol (Ki = 5 x 10(-6) M) > 5 beta-androstane-3 beta,17 beta-diol. Five other steroids, 5 beta-androstane-3 alpha,17 beta-diol, 5 alpha-androstane-3 beta,17 beta-diol, progesterone, oestradiol and oestrone, showed no inhibition at 10(-4) M. The kinetics indicate that endogenous C-19 steroids show similar competitive inhibition of the aromatase as Fadrozole. Mouse (BALB/c) preoptic aromatase was also inhibited by Fadrozole. We conclude that endogenous C-19 metabolites of testosterone are effective inhibitors of the brain aromatase, and suggest that they bind competitively at the same active site as Fadrozole.
    [Abstract] [Full Text] [Related] [New Search]